Interview with Emma Li, Brand Manager at PharmaVantage: Handling Webinar Marketing Tactics When Competitors Launch Spring Collections

Q1: Emma, imagine your biggest competitor just announced a webinar series to spotlight their new spring clinical trial collection. As a mid-level brand manager, what’s your initial move from a competitive-response perspective?

Picture this: You’re mid-morning, sipping coffee when your inbox pings with an invite to a high-profile competitor’s webinar touting their fresh pipeline updates for spring. You know many of your shared KOLs (key opinion leaders) are invited. The clock starts ticking.

Emma: My first step is speed and positioning. If competitors are stepping up their visibility with new content, we need to react quickly to ensure our portfolio's narrative isn’t drowned out. I’d convene the internal launch team immediately to assess if we have proprietary data or new outcomes we can highlight in our own webinar—even if it’s a rapid update, not a full-scale launch.

Timing matters because, in pharma, perceptions can shift fast. A 2023 PharmaExec survey found that 63% of clinical researchers form initial impressions about a drug’s innovation based on early digital content, including webinars. Missing that window is like letting the competitor own the conversation.

But speed alone isn’t enough. We have to differentiate. That means pinpointing what unique clinical insights or patient-centric data we can showcase that our rival isn’t addressing.

Q2: What are some ways to make your webinars stand out when everyone is launching their spring collections around the same time?

Emma: Differentiation in this crowded landscape is tricky but doable. Imagine two webinars both pitching phase 3 trial updates, but one is very data-heavy and static, while the other integrates patient narratives, interactive Q&A, and live polling.

One tactic we’ve used is layering in real-time audience feedback tools like Zigpoll or Slido. During a recent launch, we embedded polls asking clinicians about their biggest treatment challenges, then tailored parts of the discussion on the fly. That dynamic element boosted engagement by 7 percentage points in attendance retention.

Another approach is to lean on advanced segmentation for invitations and content. Instead of a broad “spring collection” theme, we tailor invitations to specific specialties or therapeutic areas, emphasizing the most relevant data points. For example, split invitations between oncologists and cardiologists highlighting distinct aspects of the pipeline relevant to each.

Q3: Speed is a recurring theme here. But how do you balance quick response with high-quality content, especially under tight timelines?

Emma: Good question. Quick doesn’t have to mean rushed or shallow. We try to prepare “modular” webinar content ahead of time—think of it as a toolkit of slides, case studies, and data summaries that can be rapidly customized.

For instance, before spring launches, we compile a repository of clinical trial updates, investigator profiles, and patient stories that can be mixed and matched depending on competitive moves.

That said, there’s a limitation: This approach works best if your data set is fairly stable and does not require last-minute regulatory review. If new data emerges late, quality control can slow you down. The downside is sometimes we have to delay or risk incomplete messaging.

Q4: When it comes to positioning your brand’s spring collection webinars, what messaging tactics work best against competitor claims?

Emma: Positioning is about clarifying what sets you apart. Imagine your competitor hammers the novelty of a drug delivery system, but your product shines in safety and patient adherence. We pivot to those themes.

One tactic is to frame the conversation around unmet needs the competition isn’t addressing. For example, if their webinar emphasizes efficacy, we highlight real-world tolerability data showing fewer adverse events.

We also use scenario-driven storytelling—putting clinicians in the shoes of patients managing chronic conditions with the new therapy. This resonates more than dry stats and helps KOLs visualize practical benefits.

Q5: Can you share a real example where responding quickly with a differentiated webinar moved the needle?

Emma: Sure. Last year, a competitor launched their oncology collection webinar just days before our planned one. Our team activated a “rapid response” webinar focusing on emerging biomarker data that wasn’t in their presentation.

We invited a well-known KOL as a guest speaker and added live Q&A and Zigpoll questions about biomarker prioritization. Our attendance climbed from an expected 120 to 230, and post-webinar surveys showed a 45% increase in brand favorability versus baseline.

It worked because we moved fast, picked a unique angle, and made the webinar highly interactive.

Q6: Are there risks or downsides to aggressive webinar competitive response tactics?

Emma: Definitely. If you chase every competitor move with a reactive webinar, you risk “webinar fatigue” among your audience, diminishing returns, and content dilution.

Also, overemphasizing speed might lead to compliance issues, especially if messaging isn’t thoroughly vetted. Regulatory teams often push back on last-minute content changes, so aligning earlier is crucial.

Plus, not all competitors’ launches warrant a direct response. Sometimes silence or a different channel strategy might serve better if the competitor’s offering is in a less relevant therapeutic niche.

Q7: How do you use feedback tools and post-webinar analytics to refine future competitive responses?

Emma: Feedback is gold. We deploy quick post-webinar surveys using Zigpoll and more detailed feedback through internal CRM integrations. Questions probe what data resonated, what topics were missing, and how the webinar influenced prescribing intent.

This input informs future webinar content and targeting. For example, if oncology KOLs respond better to case-based discussions than to pure data reviews, we revise accordingly.

Plus, benchmarking attendance and engagement metrics against competitor webinars—when possible—helps us identify gaps in reach or relevance. It’s a continuous learning cycle.

Q8: For mid-level brand managers aiming to sharpen webinar tactics around spring collections, what practical advice would you offer?

Emma: First, build your content toolkit early but stay flexible. Prepare modular assets that can be personalized quickly.

Second, prioritize speed—but never at the expense of quality or compliance. Engage your medical and regulatory colleagues early.

Third, focus on audience engagement. Use live polls and Q&A to make your webinars more than a monologue.

Fourth, track competitive activity constantly. Identify which launches require a response and which don’t.

Finally, integrate post-webinar feedback systematically. Tools like Zigpoll make rapid pulse checks easy.

One pharma brand I know went from 2% to 11% conversion on webinar attendees to trial enrollment by implementing these competitive-response tactics consistently over a year.

Summary Table: Webinar Tactics for Competitive Response in Pharma Spring Collection Launches

If you remember one thing, think of webinars less as static broadcasts and more as dynamic, interactive conversations—ones that require you to listen, adapt, and quickly reframe your message in response to what your competitors are saying. That’s where you win the narrative and, eventually, the market.